Kenneth Presberg, MD
Pulmonary Disease · Milwaukee, WINPI 1578515268
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $547 of the $715 with a category attached, or 76.4%. 5 manufacturers reported payments, led by United Therapeutics Corporation at 52.8% of the total. Reporting peaked in 2023 at $282 and has fallen 87.3% since, to $36 in 2025.
Across 9 payments — averaging $79.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$378
- Janssen Research & Development, LLC$166
- Bayer$136
- GSK$19
- AstraZeneca$17
Across 76 payments — averaging $17,758 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.1M
- United Therapeutics Corporation$127K
- Janssen Research & Development, LLC$84K
- Actelion Pharmaceuticals, Ltd$13K
- Actelion Pharmaceuticals US, Inc.$4K
What the payments were for
- Travel & lodging$16623%
- Food & beverage$54776%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 4 | $378 |
| Janssen Research & Development, LLC | 1 | $166 |
| Bayer | 2 | $136 |
| GSK | 1 | $19 |
| AstraZeneca | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$715 in reported general payments places this provider in the 55th percentile of 247 pulmonary disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 183 | $4,077,681 |
| AdempasRiociguat | 165 | $2,276,767 |
| OpsumitMacitentan | 152 | $1,908,459 |
| Tyvaso DpiTreprostinil | 40 | $911,484 |
| WinrevairSotatercept-Csrk | 22 | $481,330 |
| Ambrisentan | 167 | $365,514 |
| LetairisAmbrisentan | 22 | $264,513 |
| Tadalafil | 174 | $123,135 |
| Bosentan | 45 | $122,658 |
| Sildenafil Citrate | 174 | $115,325 |
| AdcircaTadalafil | 25 | $103,035 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 85 | $72,523 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 43 | $32,467 |
| EliquisApixaban | 30 | $31,625 |
| Spiriva HandihalerTiotropium Bromide | 29 | $25,548 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerAdempas | $136 | $2,276,767165 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $19 | $140,562182 claims |
| United Therapeutics CorporationAdcirca | $378 | $103,03525 claims |
| AstraZenecaSymbicort, Farxiga | $17 | $30,99871 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 247 pulmonary disease providers in Wisconsin.
Other pulmonary disease in Milwaukee
- Jonathan KurmanMilwaukee$803K
- Mouhammed RihawiMilwaukee$713K
- Kurt HuMilwaukee$55K
- Julie BillerMilwaukee$52K
- Mark BarashMilwaukee$52K
- Rahul NanchalMilwaukee$42K
- Steven LehMilwaukee$40K
- Ali MusaniMilwaukee$38K
- Michael KatzoffMilwaukee$37K
- Uzair GhoriMilwaukee$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.